文献

J-GLOBAL ID：201802243031396860   整理番号：18A0856023

進行性鼻咽頭癌における同時化学放射線療法と併用した抗EGFR剤,セツキシマブまたはニモtuの有益な効果【JST・京大機械翻訳】

Beneficial effects of anti-EGFR agents, Cetuximab or Nimotuzumab, in combination with concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma

著者 (39件)： Lin Mei (Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, 651 Dongfeng East Road, Guangzhou 510060, PR China) ,  Lin Mei (Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center; Guangzhou 510060, PR China) ,  You Rui (Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, 651 Dongfeng East Road, Guangzhou 510060, PR China) ,  You Rui (Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center; Guangzhou 510060, PR China) ,  Liu You-Ping (Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, 651 Dongfeng East Road, Guangzhou 510060, PR China) ,  Liu You-Ping (Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center; Guangzhou 510060, PR China) ,  Zhang Yi-Nuan (Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, 651 Dongfeng East Road, Guangzhou 510060, PR China) ,  Zhang Yi-Nuan (Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center; Guangzhou 510060, PR China) ,  Zhang Hao-Jiong (Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, 651 Dongfeng East Road, Guangzhou 510060, PR China) ,  Zhang Hao-Jiong (Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center; Guangzhou 510060, PR China) ,  Zou Xiong (Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, 651 Dongfeng East Road, Guangzhou 510060, PR China) ,  Zou Xiong (Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center; Guangzhou 510060, PR China) ,  Yang Qi (Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, 651 Dongfeng East Road, Guangzhou 510060, PR China) ,  Yang Qi (Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center; Guangzhou 510060, PR China) ,  Li Chao-Feng (Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center; Guangzhou 510060, PR China) ,  Li Chao-Feng (Department of Information Technology, Sun Yat-sen University Cancer Center, 651 Dongfeng East Road, Guangzhou 510060, PR China) ,  Hua Yi-Jun (Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, 651 Dongfeng East Road, Guangzhou 510060, PR China) ,  Hua Yi-Jun (Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center; Guangzhou 510060, PR China) ,  Yu Tao (Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, 651 Dongfeng East Road, Guangzhou 510060, PR China) ,  Yu Tao (Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center; Guangzhou 510060, PR China) ,  Cao Jing-Yu (Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, 651 Dongfeng East Road, Guangzhou 510060, PR China) ,  Cao Jing-Yu (Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center; Guangzhou 510060, PR China) ,  Li Ji-Bin (Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center; Guangzhou 510060, PR China) ,  Li Ji-Bin (Department of Clinical Research, Sun Yat-sen University Cancer Center, 651 Dongfeng East Road, Guangzhou 510060, PR China) ,  Mo Hao-Yuan (Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, 651 Dongfeng East Road, Guangzhou 510060, PR China) ,  Mo Hao-Yuan (Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center; Guangzhou 510060, PR China) ,  Guo Ling (Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, 651 Dongfeng East Road, Guangzhou 510060, PR China) ,  Guo Ling (Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center; Guangzhou 510060, PR China) ,  Lin Ai-Hua (Department of Medical Statistics and Epidemiology, School of Public Health, Sun Yat-sen University, 74 Zhongshan Second Road, Guangzhou 510080, PR China) ,  Sun Ying (Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, 651 Dongfeng East Road, Guangzhou 510060, PR China) ,  Sun Ying (Department of Radiation Oncology, Sun Yat-sen University Cancer Center, 651 Dongfeng East Road, Guangzhou 510060, PR China) ,  Qian Chao-Nan (Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, 651 Dongfeng East Road, Guangzhou 510060, PR China) ,  Qian Chao-Nan (Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center; Guangzhou 510060, PR China) ,  Ma Jun (Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, 651 Dongfeng East Road, Guangzhou 510060, PR China) ,  Ma Jun (Department of Radiation Oncology, Sun Yat-sen University Cancer Center, 651 Dongfeng East Road, Guangzhou 510060, PR China) ,  Mai Hai-Qiang (Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, 651 Dongfeng East Road, Guangzhou 510060, PR China) ,  Mai Hai-Qiang (Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center; Guangzhou 510060, PR China) ,  Chen Ming-Yuan (Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, 651 Dongfeng East Road, Guangzhou 510060, PR China) ,  Chen Ming-Yuan (Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center; Guangzhou 510060, PR China)
資料名： Oral Oncology  (Oral Oncology)
巻： 80  ページ： 1-8  発行年： 2018年 
JST資料番号： A1166A  ISSN： 1368-8375  資料種別： 逐次刊行物 (A)
記事区分： 原著論文  発行国： オランダ (NLD)  言語： 英語 (EN)

抄録/ポイント： 本研究は,同時化学放射線療法(CCRT)+Cetuximab(CTX)またはニモツズマブ(NTZ)を受けている局所進行性鼻咽頭癌(NPC)患者における有効性と安全性を,誘導化学療法(IC)+CCRTを受ける患者と比較して評価することを目的とした。2008年1月から2013年12月まで,715人の適格患者を本研究に登録した。性別,年齢,Karnofsky性能状態(KPS),腫瘍ステージ,結節ステージ,および臨床ステージを調整する傾向スコアを用いて,ICT/NTZプラスCCRT(137患者)を受けた各患者をICプラスCCRT(274患者)を受けた2患者と一致させてバランスのとれたコホートを作成した。一次エンドポイントは全生存(OS)であり,他の転帰変数は無病生存(DFS),遠隔転移のない生存(DMFS)および局所無再発生存(LRRFS)を含んだ。追跡期間の中央値は,CTX/NTZ+CCRT群およびIC+CCRT群に対して,それぞれ57.0か月および55.0か月であった。3年OS(95.5%対94.7%,P=0.083),3年DMFS(93.3%対92.5%,P=0.243)および3年LRRFS(97.0%対95.1%,P=0.297)において,CTX/NTZ+CCRT群とIC+CCRT群の間に有意差は見られなかった。ICプラスCCRTを受けている患者は,CTX/NTZプラスCCRTで治療された患者と比較して,重篤な血液学的毒性と下痢を患った。CTT/NTZとCCRTの併用は,局所的に進行したNPC患者に対する生存転帰におけるICプラスCCRT治療に匹敵するが,ICプラスCCRT治療よりも良好な安全性プロフィールを有する。Copyright 2018 Elsevier B.V., Amsterdam. All rights reserved. Translated from English into Japanese by JST.【JST・京大機械翻訳】

シソーラス用語： 腫瘍 ,  安全性 ,  *EGF受容体 ,  毒性 ,  中央値 ,  母集団 ,  患者 ,  薬物療法
準シソーラス用語： 有害事象 ,  *放射線化学療法 ,  有意差 ,  遠隔転移 ,  転帰 ,  *セツキシマブ ,  *同時化学放射線療法 , 【Automatic Indexing@JST】

著者キーワード (7件)： 上咽頭癌 ,  IMRT ,  化学放射線療法 ,  ニモtu ,  セツキシマブ ,  生存転帰 ,  有害事象

分類 (1件)： 腫ようの放射線療法  (GE03034K)

タイトルに関連する用語 (6件)： 鼻咽頭癌 ,  同時化学放射線療法 ,  併用 ,  EGFR ,  セツキシマブ ,  TU